Neoadjuvant anthracycline-free versus anthracycline-containing chemotherapy combined with dual HER2 blockade in HER2-positive breast cancer: a real-world comparative study.

Breast Cancer Res · 2026 · PMC13403388 · PMID 42210329

Europe PMC DOI

hedged sentence

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

a nonsignificant trendp = 0.073so close (0.05 < p ≤ 0.1)

Treatment with TCHP/TCH showed a nonsignificant trend toward increased pCR compared with anthracycline-containing regimens (OR, 2.03; p = 0.073).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.